As the global obesity epidemic intensifies, the demand for metabolic health interventions—specifically GLP-1 receptor agonists and high-purity peptides—has reached an unprecedented scale. Gentolex Group provides a comprehensive framework for international enterprises to navigate this complex landscape.
The global metabolic therapy market is projected to exceed $100 billion by 2030. Industrial procurement is shifting from raw bulk chemicals to "Ready-to-Use" lyophilized formulations. We address this by providing scalable cGMP manufacturing that bridges the gap between lab-scale synthesis and mass-market supply.
Enterprises now prioritize Chain of Custody (CoC) and purity validation. Procurement managers from North America, Europe, and Southeast Asia require COA, HPLC, and MS reports as standard. Our procurement services simplify this by acting as a single point of contact for complex peptide sequences like Tirzepatide and Semaglutide.
Localization is key. Gentolex maintains representatives in Mexico and South Africa to provide local logistical support, ensuring that imports comply with specific regional health authority mandates and custom regulations for pharmaceutical intermediates.
Gentolex's technical roadmap focuses on the synthesis of Long-Acting Peptides. By utilizing advanced Fmoc-protected amino acid strategies and automated solid-phase peptide synthesis (SPPS), we achieve purity levels of 99%+. Our current R&D is focused on:
Our overall factory construction area of 250,000 square meters is built under international standards to offer flexible, scalable, and cost-effective solutions for global partners.
Countries Served
Average Purity
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions. We provide an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations.
Development of synthetic heptapeptide TKPRPGP for neuropharmacological research and global supply.
View Details
Providing high-quality Tβ4 solutions for biotechnology companies and research organizations.
View Details
Synthetic pentadecapeptide for tissue repair and gastrointestinal protection research.
View Details
Neuroactive peptide derived from ACTH fragment for advanced life science investigation.
View Details
Mitochondria-targeting tetrapeptide designed to support cellular bioenergetics.
View DetailsA: For research and pharmaceutical application, we ensure a minimum of 98% purity, with most batches reaching 99.5% via HPLC validation to ensure maximum efficacy and safety.
A: We utilize cold-chain logistics where necessary and offer lyophilized (freeze-dried) powder forms which are highly stable at room temperature for international transit.
A: Yes, our facility specialized in custom peptide synthesis, allowing for modifications in amino acid sequences to meet specific R&D requirements.
